Literature DB >> 17302889

Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients.

U Feger1, C Luther, S Poeschel, A Melms, E Tolosa, H Wiendl.   

Abstract

Naturally occurring CD4+ CD25+ regulatory T cells (nTreg) play a major role in controlling autoimmunity by suppressing self-reactive T cells. Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central nervous system (CNS), where T cells play a key role in orchestrating tissue damage. While CD4+ CD25+ nTreg have been investigated in peripheral blood from MS patients, little is known about their presence and possible function within the target organ, the CNS. In order to study whether these cells are present in the cerebrospinal fluid (CSF) under pathological conditions, we have analysed the frequency of CD4+ CD25+ nTreg in peripheral blood and CSF from MS patients (n=14), patients with other neurological disorders (OND; n=9) and compared peripheral levels with healthy controls (n=40). We found that the frequency of CD4+ CD25+ forkhead transcription factor 3 (FOXP3)+ nTreg was significantly elevated in the CSF from MS patients (mean CSF=4 x 05 +/- 1.54% versus mean peripheral blood = 2 x 93 +/- 0 x 94%) but not from patients with other neurological disorders (mean CSF = 3 x 78 +/- 1 x 26% versus mean peripheral blood = 3 x 74 +/- 1 x 4%). The frequency of nTreg in the periphery did not differ between MS patients and healthy donors; however, nTreg from MS patients showed reduced suppressive capacity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17302889      PMCID: PMC1810482          DOI: 10.1111/j.1365-2249.2006.03271.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

Review 1.  Regulatory T cells under scrutiny.

Authors:  Jean-François Bach; Jean François Bach
Journal:  Nat Rev Immunol       Date:  2003-03       Impact factor: 53.106

2.  Circulating dendritic cells subsets and regulatory T-cells at multiple sclerosis relapse: differential short-term changes on corticosteroids therapy.

Authors:  Joaquín Navarro; Carol Aristimuño; Silvia Sánchez-Ramón; Dolores Vigil; Ma Luisa Martínez-Ginés; Eduardo Fernández-Cruz; Clara de Andrés
Journal:  J Neuroimmunol       Date:  2006-05-15       Impact factor: 3.478

3.  Multiple immuno-regulatory defects in type-1 diabetes.

Authors:  Anjli Kukreja; Giulia Cost; John Marker; Chenhui Zhang; Zhong Sun; Karen Lin-Su; Svetlana Ten; Maureen Sanz; Mark Exley; Brian Wilson; Steven Porcelli; Noel Maclaren
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 4.  Pathogenesis of multiple sclerosis: an update on immunology.

Authors:  Bernhard Hemmer; Sabine Cepok; Stefan Nessler; Norbert Sommer
Journal:  Curr Opin Neurol       Date:  2002-06       Impact factor: 5.710

5.  Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis.

Authors:  Duojia Cao; Vivianne Malmström; Clare Baecher-Allan; David Hafler; Lars Klareskog; Christina Trollmo
Journal:  Eur J Immunol       Date:  2003-01       Impact factor: 5.532

6.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

7.  CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis.

Authors:  Ismé M de Kleer; Lucy R Wedderburn; Leonie S Taams; Alka Patel; Hemlata Varsani; Mark Klein; Wilco de Jager; Gisela Pugayung; Francesca Giannoni; Ger Rijkers; Salvatore Albani; Wietse Kuis; Berent Prakken
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

8.  Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs.

Authors:  Prabhakar Putheti; Asa Pettersson; Mats Soderstrom; Hans Link; Yu Min Huang
Journal:  J Clin Immunol       Date:  2004-03       Impact factor: 8.317

9.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

10.  Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.

Authors:  Vissia Viglietta; Clare Baecher-Allan; Howard L Weiner; David A Hafler
Journal:  J Exp Med       Date:  2004-04-05       Impact factor: 14.307

View more
  65 in total

Review 1.  The Gut Microbiome and Multiple Sclerosis.

Authors:  Javier Ochoa-Repáraz; Trevor O Kirby; Lloyd H Kasper
Journal:  Cold Spring Harb Perspect Med       Date:  2018-06-01       Impact factor: 6.915

2.  Polymorphisms in the IL2, IL2RA and IL2RB genes in multiple sclerosis risk.

Authors:  María L Cavanillas; Antonio Alcina; Concepción Núñez; Virginia de las Heras; Miguel Fernández-Arquero; Manuel Bartolomé; Emilio G de la Concha; Oscar Fernández; Rafael Arroyo; Fuencisla Matesanz; Elena Urcelay
Journal:  Eur J Hum Genet       Date:  2010-02-24       Impact factor: 4.246

Review 3.  Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored?

Authors:  Arthur A Vandenbark; Halina Offner
Journal:  Immunology       Date:  2008-09       Impact factor: 7.397

4.  Chronic reactive gliosis following regulatory T cell depletion during acute MCMV encephalitis.

Authors:  James R Lokensgard; Scott J Schachtele; Manohar B Mutnal; Wen S Sheng; Sujata Prasad; Shuxian Hu
Journal:  Glia       Date:  2015-06-04       Impact factor: 7.452

Review 5.  Heterogeneity and Stability in Foxp3+ Regulatory T Cells.

Authors:  Booki Min
Journal:  J Interferon Cytokine Res       Date:  2017-07-11       Impact factor: 2.607

6.  Administration of CD4+CD25highCD127-FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study.

Authors:  Kamil Chwojnicki; Dorota Iwaszkiewicz-Grześ; Anna Jankowska; Maciej Zieliński; Paweł Łowiec; Mateusz Gliwiński; Małgorzata Grzywińska; Kamil Kowalczyk; Aleksandra Konarzewska; Paulina Glasner; Justyna Sakowska; Julia Kulczycka; Anna Jaźwińska-Curyłło; Marlena Kubach; Bartosz Karaszewski; Walenty Nyka; Edyta Szurowska; Piotr Trzonkowski
Journal:  BioDrugs       Date:  2021-01-05       Impact factor: 5.807

7.  A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis.

Authors:  Carlos Riveros; Drew Mellor; Kaushal S Gandhi; Fiona C McKay; Mathew B Cox; Regina Berretta; S Yahya Vaezpour; Mario Inostroza-Ponta; Simon A Broadley; Robert N Heard; Stephen Vucic; Graeme J Stewart; David W Williams; Rodney J Scott; Jeanette Lechner-Scott; David R Booth; Pablo Moscato
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

8.  Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis.

Authors:  Sebastian Doerck; Kerstin Göbel; Gesa Weise; Tilman Schneider-Hohendorf; Michael Reinhardt; Peter Hauff; Nicholas Schwab; Ralf Linker; Mathias Mäurer; Sven G Meuth; Heinz Wiendl
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

9.  Physical Exercise Attenuates Experimental Autoimmune Encephalomyelitis by Inhibiting Peripheral Immune Response and Blood-Brain Barrier Disruption.

Authors:  Priscila S Souza; Elaine D Gonçalves; Giulia S Pedroso; Hemelin R Farias; Stella C Junqueira; Rodrigo Marcon; Talita Tuon; Maíra Cola; Paulo C L Silveira; Adair R Santos; João B Calixto; Cláudio T Souza; Ricardo A de Pinho; Rafael C Dutra
Journal:  Mol Neurobiol       Date:  2016-07-22       Impact factor: 5.590

Review 10.  Immunopathology of multiple sclerosis.

Authors:  Calliope A Dendrou; Lars Fugger; Manuel A Friese
Journal:  Nat Rev Immunol       Date:  2015-08-07       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.